Novel insights on GM1 and Parkinson's disease: A critical review
Authors (first, second and last of 6)
Collection
The Glycobiology of Parkinson’s disease
Parkinson’s disease is a major neurodegenerative disorder affecting millions of people and there is no currently available disease modifying agent to slow or stop the progression of the disease. This collection of manuscripts helps bring together our understanding of 'The Glycobiology of Parkinson's Disease'.
Editors
-
Prof. Sandro Sonnino
Professor Sandro Sonnino is President of the 'International Glycoconjugate Organization' and Editor-in-Chief of the Glycoconjugate Journal. He is affiliated to the: Department of Medical Biotechnology and Translational Medicine, University of Milan, Via Fratelli Cervi 93, 20090 Segrate (Mi), Italy.
Articles (3 in this collection)
-
-
Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson’s disease
Authors (first, second and last of 4)
-
